Lurie Cancer Center Director to Join City of Hope

AFTER 32 YEARS at Northwestern University Feinberg School of Medicine, Steven T. Rosen, MD, Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, has accepted an offer to become provost and scientific director at City of Hope, a cancer research hospital in Duarte, California.

Established in 1974, Northwestern’s cancer center has enjoyed an era of international prominence under the leadership of Rosen, who became Director in 1989. In 1991 it was dedicated as the Robert H. Lurie Cancer Center of Northwestern University through the transformative gift of Ann and Robert H. Lurie.

In 1998, the center’s name was modified to signify the National Cancer Institute (NCI) designation of the highly competitive “comprehensive” title — reflecting its dedication to the utmost standards of cancer research, patient care, education, and community outreach. Rosen is the principal investigator on the NCI Cancer Center Support Grant (CCSG) which received the Lurie Cancer Center's highest rating, an overall “Outstanding,” on its 2013 competitive renewal. The Lurie Cancer Center is also a founding member of the National Comprehensive Cancer Network and the Big Ten Cancer Research Consortium.

Heavy Smoking Raises Prostate Cancer Risk in African Americans

IN A STUDY of heavy smokers (20 or more cigarettes per day), Adam Murphy, MD, assistant professor of urology at Feinberg, reports that blacks have more than two and a half times the risk of developing prostate cancer and are nearly twice as likely as light or nonsmokers to be diagnosed with a higher-grade, more aggressive form of the disease. In comparison, the scientists found no evidence of the correlation in European American men.

“This specific link between smoking and prostate cancer is extremely relevant because 70 percent of African Americans who smoke use menthol-containing cigarettes, which are harder to quit,” said Murphy, a member of the Lurie Cancer Center and the Center for Community Health. “These findings add to the list of reasons to limit the selling of menthol cigarettes, as the Food and Drug Administration has proposed.”
Incurable Brain Cancer Gene Is Silenced

HELP IS CRITICAL for patients with glioblastoma multiforme (GBM): The median survival rate is 14 to 16 months, and approximately 16,000 new cases are reported in the U.S. every year. Now a Northwestern University research team is the first to demonstrate delivery of a drug that turns off a critical gene in this complex cancer.

The novel therapeutic, which is based on nanotechnology, is small and nimble enough to cross the blood-brain barrier and get to where it is needed -- the brain tumor. Designed to target a specific cancer-causing gene in cells, the drug simply flips the switch of the troublesome oncogene to "off," silencing the gene. This knocks out the proteins that keep cancer cells immortal.

"This is a beautiful marriage of a new technology with the genes of a terrible disease," said Lurie Cancer Center member Chad A. Mirkin, PhD, a nanomedicine expert and a senior co-author of the study. "Using highly adaptable spherical nucleic acids, we specifically targeted a gene associated with GBM and turned it off in vivo. This proof-of-concept further establishes a broad platform for treating a wide range of diseases, from lung and colon cancers to rheumatoid arthritis and psoriasis." Mirkin is the George B. Rathmann Professor of Chemistry in the Weinberg College of Arts and Sciences and professor of medicine, chemical and biological engineering, biomedical engineering and materials science and engineering.

Mirkin paired up with glioblastoma expert Alexander H. Stegh, PhD, a Lurie Cancer Center member and an assistant professor of neurology at Feinberg. "GBM is a very challenging cancer, and most chemo-therapeutic drugs fail in the clinic," said Stegh, a senior co-author of the study. "The beauty of the gene we silenced in this study is that it plays many different roles in therapy resistance. Taking the gene out of the picture should allow conventional therapies to be more effective." Both Mirkin and Stegh are investigators in the Northwestern Brain Tumor Institute.

Platelet Production Affected by Key Protein

A CRITICAL PROTEIN in the formation of normal platelets has been discovered that could someday help turn large-scale production of the blood product into a reality. "What we found is a novel mechanism for how platelet precursors are generated," said principal investigator Seth Corey, MD, MPH, professor in pediatrics-hematology, oncology, and stem cell transplantation and cell and molecular biology at the Feinberg School of Medicine and a member of the Lurie Cancer Center. "The loss of CIP4, a protein that bridges the barrier of these cells with their skeleton-like infrastructure, causes a defect in platelet production." The discovery was recently published in the journal Blood.

Corey’s lab confirmed in animal models and cell lines that a loss of CIP4 resulted in a decreased number of pro-platelet projections, causing a decreased number of platelets. "This shortage either represents a production defect or a destruction problem and we think in this case, it is the former," said Corey, a member of the Ann & Robert H. Lurie Children’s Hospital of Chicago Research Center. “Somehow the loss of CIP4 is preventing the production of an optimal number of normal platelets.”

When the body is unable to keep up with demand – as can be the case during surgery, chemotherapy, or bone marrow transplantation – a platelet transfusion is done. Donated platelets are always in short supply, but Corey believes the quest to efficiently produce them in tissue culture may be nearing a successful conclusion. "The more we understand about how platelets are produced, the closer we can get to engineering an artificial system to create ones that are healthy and tolerated by all."

» Read more
Lurie Cancer Center Designated a National Center of Excellence in AYA Oncology

THE LURIE CANCER CENTER has been designated a Change it Back National Center of Excellence in Adolescent and Young Adult Oncology. The Lurie Cancer Center is one of only two cancer centers in the nation to hold this honor, recognizing them as a leader in the field of Adolescent and Young Adult (AYA) cancer care.

The award was presented in Cleveland, Ohio at Connect the Dots, the annual conference of Critical Mass / The Young Adult Cancer Alliance. A member of Critical Mass since 2009, the Lurie Cancer Center formed a multidisciplinary working group to improve standards of care and outcomes for patients diagnosed with cancer between the ages of 15 and 39.

“One of our primary goals is providing AYA cancer survivors with the tools to become effective self-advocates,” said Lurie Cancer Center Clinical Psychologist Stacy Sanford, PhD, who founded the working group. “AYAs may encounter a range of concerns specific to their development stage including difficulties with reentry into school or the workforce, insurance coverage, infertility or parenting through cancer, sexual health, relationships or dating, emotional distress, or late effects from treatment including risk for secondary malignancies. Programs offering support and information about the unique challenges they may encounter, help prepare AYAs to ask tough, but critical questions before, during and after cancer treatment.”

Contact Stacy Sanford for information about ways to become involved with the AYA oncology program.

Genetic Test Determines Melanoma Severity

KNOWING WHICH MELANOMAS are likely to be cured with surgery and which are likely to spread is the basis for a new clinical test recently validated by Pedram Gerami, MD, associate professor in dermatology at the Feinberg School of Medicine and a member of the Lurie Cancer Center.

“The significance of this study is that we can provide patients and their healthcare providers greater accuracy than before in predicting how melanomas, the most dangerous form of skin cancer, will react,” said Gerami, director of melanoma research at Northwestern’s Skin Cancer Institute. “These findings give us one additional way to characterize melanomas, classify them, and allow us to fine tune treatment plans for individual needs.”

Gerami’s data, disseminated at the Summer Academy Meeting of the American Academy of Dermatology, confirmed previous studies that showed a specific genetic test was a strong predictor of which Stage I or II non-metastatic skin cancers will likely recur.

“The test will help save some patients with low-grade melanomas part of the undue burden of certain treatments used in aggressive melanomas and likewise make sure patients who do have aggressive disease get the treatment they need,” Gerami said.

Gerami’s lab uses molecular techniques to improve diagnosis and prognosis in melanomas. He recently published a protocol for determining whether a tumor is melanoma or not when standard microscopy – a common way to diagnose the disease – fails to do so. The lab is currently evaluating an adhesive skin tape to non-invasively evaluate genetic material from moles.
Inhibitor May Help Treat Acute Myeloid Leukemia

A GROUP OF inhibitors currently in clinical trials for the treatment of solid tumors may prove useful in targeting a treatment-resistant subset of acute myeloid leukemia (AML), a cancer that arises from the bone marrow. Elizabeth Eklund, MD, professor in hematology/oncology at the Feinberg School of Medicine, is working to determine if two proteins increase the production of a specific growth factor (Fgf2), which in turn promotes growth of leukemia cells.

If true, an Fgf2 receptor inhibitor might be used to augment chemotherapy or prevent relapse in individuals with AML. Eklund, a member of the Lurie Cancer Center, has been awarded a Leukemia and Lymphoma Society (LLS) Translational Research grant to pursue her hypothesis.

» Read more

Two-Question Survey Effectively Screens Cancer Patients for Depression

CANCER PATIENTS receiving radiotherapy can be effectively screened for depression using a simple, easily administered two-item questionnaire, according to a study presented at the 55th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in September. Lynne Wagner, PhD, Associate Professor in the Department of Medical Social Sciences at the Feinberg School of Medicine and a member of Lurie Cancer Center is Principal Investigator of the Radiation Therapy Oncology Group (RTOG) Community Clinical Oncology Program (CCOP) study.

“This study was designed to test the feasibility of screening for major depression in cancer patients receiving radiation therapy. The ability of a two-question survey to effectively screen for depression will hopefully prompt more centers to screen and to refer patients in need of mental health services,” said Wagner.

» Read more

Read the Cancer Letter Anywhere

THE LURIE CANCER CENTER has purchased a one year site license for The Cancer Letter, an award-winning weekly newsletter providing news about cancer research funding, legislation, policy issues, drug development and people in the news. It is available to faculty and staff using Northwestern Memorial Hospital, Northwestern University and Northwestern Medical Faculty Foundation e-mail addresses.

Log in to read The Cancer Letter
For remote access, user name is TCL@northwestern.edu and password is 123456

NCCN Launches eBulletin for Member Institutions

THE NATIONAL COMPREHENSIVE CANCER NETWORK announced development of a new newsletter specifically for NCCN Member Institutions. Beginning in 2014, it will be published on a regular basis featuring information pertinent to NCCN Member Institutions, including the benefits and services received through the Lurie Cancer Center’s membership in NCCN.

The publication is part of an effort to engage faculty and staff at Member Institutions, and keep them informed about NCCN programs and initiatives. It will not be a duplicate of the bi-weekly NCCN newsletter.

Please send a message to MIRelations@nccn.org to be added to the mailing list.
Awards & Honors

Seth Corey, MD, MPH, Professor in Pediatrics-Hematology, Oncology and Stem Cell Transplantation and Cell and Molecular Biology at Feinberg, is the recipient of a Bridge Grant from the American Society of Hematology (ASH).

Chad Mirkin, PhD, George B. Rathmann Professor of Chemistry in the Weinberg College of Arts and Sciences and Professor of Medicine, Chemical and Biological Engineering, Biomedical Engineering and Materials Science and Engineering, was named a 2013 Thomson Reuters Citation Laureate in its annual pre-Nobel Prize study. He is Director of Northwestern’s International Institute for Nanotechnology.

Teri Odom, PhD, Professor of Chemistry at the Weinberg College of Arts and Sciences, has been named Executive Editor for ACS Phototonics, a new journal launched by ACS Publications.

Christian Petersen, PhD, Assistant Professor of Molecular Biosciences at the Weinberg College of Arts and Sciences, has received the NIH Director’s New Innovator Award, part of the High Risk-High Reward program supported by the NIH Common Fund. “This program allows researchers to propose highly creative research projects across a broad range of biomedical research areas, that involve inherent risk, but have the potential for high rewards,” NIH Director Francis S. Collins said.

The Northwestern University Board of Trustees announced 16 new named professorships, including the following members of the Lurie Cancer Center:

Orin Bloch, MD, Assistant Professor of Neurological Surgery, to the Khatib Professorship of Neurological Surgery

James P. Chandler, MD, Professor of Neurological Surgery, to the Lavin/Fates Professorship of Neurological Surgery

Carole LaBonne, PhD, Professor of Molecular Biosciences, to the Arthur E. Anderson Research/Training Professorship

Kelly Mayo, PhD, Professor of Molecular Biosciences and Neurobiology, to the Walter and Jennie Bayne Professorship

The Office of the Provost at Northwestern University has selected the following Lurie Cancer Center members as Public Voices Thought Leadership Fellows for 2013-2014. This year-long program provides a select group of scholars across all disciplines with the resources, support and skills needed in order to dramatically increase their visibility and influence as thought leaders in academia and the world at large.

Sofia Garcia, PhD, Assistant Professor of Medical Social Sciences, Psychiatry, and Behavioral Sciences, Feinberg School of Medicine

Mita Goel, MD, MPH, Assistant Professor of Internal Medicine, and Geriatrics, Feinberg

June McKoy, MD, MPH, JD, MBA, Associate Professor of Geriatrics, Internal Medicine, and Preventive Medicine, Feinberg

Melissa Simon, MD, MPH, Associate Professor, Obstetrics and Gynecology, Preventive Medicine, and Medical Social Sciences, Feinberg

» Read more
Patient & Public Programs

THE LURIE CANCER CENTER is committed to educating the public about cancer prevention and treatment, and offers a wide range of community events and patient programs throughout the year. Below is a list of programs scheduled through January 2014.

LEARN MORE AND REGISTER AT cancer.northwestern.edu or call 312.695.1304.

Cancer Connections
Saturday, November 16, 2013
Feinberg Pavilion, 3rd floor

Offered quarterly, this series of public education events is dedicated to improving the quality of life for patients, their families and caregivers—during and after cancer treatment. Topics planned for this month’s program include, “Breakfast Warriors”, “The Affordable Care Act: How Will it Affect Me?”, “Music and Healing”, “Planning for the Future: How Do Advanced Directives Fit In?” and “Spirituality and Living with Cancer”.

Cutaneous T-Cell Lymphoma Educational Forum
Tuesday, December 10, 2013
Robert H. Lurie Medical Research Center, Baldwin Auditorium

Patients and caregivers are invited to this free program hosted in partnership with the Cutaneous Lymphoma Foundation. Experts will discuss topical therapies, clinical trials and new treatments in addition to answering questions.

Gilda’s Club Chicago at the Lurie Cancer Center

Lurie Cancer Center patients and families have on-site access to a wide range of programs offered by Gilda’s Club Chicago. Designed to be fun, informative and reduce stress, all activities are offered free of charge. The newest addition is knitting, offered on Thursday mornings in Galter Pavilion, 21st floor.

Shine a Light on Lung Cancer Vigil
“Virtual Vigil” Photo Album Online

People impacted by lung cancer around the world are joining together for the Lung Cancer Alliance’s 5th annual “Shine a Light on Lung Cancer” Vigils throughout November. Northwestern Medicine and the Lurie Cancer Center created a photo album to connect newly-diagnosed lung cancer patients, long-term survivors, caregivers and healthcare professionals. View the album and consider posting your own photo during Lung Cancer Awareness Month.
Professional Programs

THROUGHOUT THE YEAR, the Lurie Cancer Center offers professional education on various cancer related topics. Below is a list of programs scheduled through January, 2014.

LEARN MORE AND REGISTER AT cancer.northwestern.edu or call 312.695.1304.

16th Annual Oncology Nursing Conference
Friday, November 22, 2013
Feinberg Pavilion
Keynote Speaker: Frank Giles, MD
Director, Developmental Therapeutics Institute
Chairs: Peggy Gilbertsen, RN
Mary Callaghan, RN, MN, AOCNS

This highly visible and successful conference attracts over 250 oncology nurses each year from around the region. In addition to the Keynote Speech on “The Role of Nursing in Developmental Therapeutics”, topics include: “Clinical Trials: Myths and Barriers,” “Cancer Survivorship: The Changing Role of the Nurse,” “Childhood Cancer and Hematopoietic Stem Cell Transplant: Survivorship & Transition,” and “Sexuality and Cancer.”

Signal Transduction and Molecular Regulation Journal Club
Friday, November 22, 2013
Pancoe-NSUHS Life Sciences Pavilion, 4103
Sponsored by Signal Transduction in Cancer
Contact: RoliMandhana2015@u.northwestern.edu

Staffileno Head and Neck Cancer Dental Symposium
Friday, January 17, 2014
Feinberg Pavilion
Chairs: Chairs: Mark Agulnik, MD,
Mark Hutten, DDS, Bharat Mittal, MD,
Harold Pelzer, MD, DDS, Samir Sejpal, MD

The symposium will feature educational sessions on diagnosis, disease treatment and long-term management of head and neck cancer patients, focusing on the integral role of the dental team working in conjunction with the medical team. Hosted in partnership with the American College of Prosthodontists and the American Academy of Maxillofacial Prosthetics.

Grand Rounds & Tumor Cell Biology

GRAND ROUNDS
Fridays: 8:00 a.m. to 9:00a.m
Robert H. Lurie Medical Research Center
303 E. Superior, Chicago
Gray Conference Room (unless otherwise noted)

Presented by the Division of Hematology/Oncology and the Lurie Cancer Center, the weekly Grand Rounds update physicians and healthcare personnel on developing trends and techniques in medicine.

» View the Grand Rounds Schedule here

TUMOR CELL BIOLOGY
Thursdays: 1:00 p.m. to 2:00 p.m.
Robert H. Lurie Medical Research Center
303 E. Superior, Chicago
Baldwin Auditorium (unless otherwise noted)

The Tumor Cell Biology Seminars present weekly updates on novel translational cancer research in the areas of tumor biology, biomedical informatics and cancer prevention and diagnosis.

» View the Tumor Cell Biology Seminar Schedule here

If you would like to receive weekly reminders about the Grand Rounds and/or TCB Seminar schedules please contact Denise Marshall at d-marshall4@northwestern.edu.

Cancer & Fertility Virtual Grand Rounds

The Oncofertility Consortium has created a series of Virtual Grand Rounds, primarily for the clinical community, to increase reproductive education among oncology and reproductive providers. Learn more about how specific chemotherapeutic drugs and radiation treatments used to treat brain cancer, can impact fertility. Providers can also get information about the latest fertility preservation options, get access to reproductive specialists in their region, and receive free CME credits through this program, which is accessible via computer or mobile device.

Illinois oncology providers interested in connecting with other providers and reproductive specialists in the Illinois area can participate in the Consortium’s pilot program to increase oncofertility communication and education. E-mail Angie Krausfeldt or call her at 312.503.2506 to learn more.

» View the Oncofertility Virtual Grand Rounds Schedule here
Funding Opportunities

Travel Grants

The Katten Muchin Rosenman Travel Scholarship Program allows doctoral students and postdoctoral fellows to present the results of their basic cancer research.

The Center for Genetic Medicine (CGM) Travel Fellowship allows doctoral students and postdoctoral fellows to present the results of their basic cancer research showing its genetics relevance.

The Cancer Prevention Travel Scholarship Program allows doctoral students and postdoctoral fellows to present the results of their laboratory, clinical, population or behavioral research with implications for cancer prevention.

The next deadline to apply for 2013 Travel Fellowship Awards is March 7, 2013.

>>> Details and Application Process for Academic Year 2013-2014

Basic Sciences Research Division

H Foundation Incentive Awards provide funding for faculty who have submitted and received a score on a RO1 grant to the NCI for the first time in their career. If additional funds are available, awards will be made to other faculty for new, first-time NCI RO1 submissions, which are scored but not yet funded.

H Foundation Bridge Awards provide up to $20,000 of support for competing renewals of NCI-sponsored RO1 research that missed the payline.

Applications for H Foundation Incentive and Bridge Awards are reviewed on a rolling basis and accepted until funds for the year are expended.

>>> Details and Application Process

Lea Charitable Trust Equipment Grants

Through the generous support of the Lea Charitable Trust, a pool of funds is available to full members of the Lurie Cancer Center affiliated with one of the Basic Sciences Research Programs for use by multiple investigators or to support small equipment grants for collaborative research projects.

Lea Charitable Trust Equipment Grants are made on a rolling basis as funds become available.

>>> Details and Application Process

Cancer Support-Team Awards

The Lurie Cancer Center is seeking applications for Cancer Support-Team Awards. The goals of these awards are to increase research in cancer prevention, control and survivorship, to foster the development of new interdisciplinary research teams that focus upon important problems and do so in a novel and effective manner, and to provide a pathway by which investigators can generate preliminary information that will serve to optimize their chances of successfully competing for national level peer reviewed funding.

Two awards, up to $50,000 each are anticipated. Projects must focus on a single problem relevant to cancer prevention, control and/or survivorship.

Deadline: December 19, 2013

>>> Details and Application Process
Welcome New Members

Lurie Cancer Center Appoints New Members

**Orin Bloch, MD**, is Assistant Professor in Neurological Surgery at Feinberg. His primary research interest is in the development of immunotherapy for the treatment of malignant gliomas. He has been closely involved in phase I and II clinical trials of a heat-shock protein peptide complex vaccine for glioblastoma, which is known to highly immunosuppressive. In his laboratory, he studies mechanisms by which gliomas induce local immunoresistance and systemic immunosuppression in hope of identifying targets to modulate immunity in glioma patients that can be combined with active immunotherapy.

Contact Dr. Bloch at 312.695.3799 or orin.bloch@northwestern.edu

**Matthew Clutter, PhD**, is Senior Research Associate, Center for Molecular Innovation & Drug Discovery (CMIDD). He works in CMIDD’s High Throughput Lab, developing and running small molecule screens to identify compounds with potential application to oncology and other disease areas—primarily developing high throughput cell-based assays to measure cell signaling that enable identification of protein kinase inhibitors. Clutter is interested in initiating collaborative drug discovery projects that connect Lurie Cancer Center investigators with resources and scientists in the CMIDD.

Contact Dr. Clutter at 847.491.5960 or matt.clutter@northwestern.edu

**Priya Kumthekar, MD**, is Assistant Professor in Neurology at Feinberg. Her neuro-oncology clinical and research interests include metastatic disease and quality of life/adjunct care in brain tumors. She has current and upcoming clinical trials in CNS metastatic disease from systemic solid tumors. In addition, Kumthekar is creating an integrative program with the Rehabilitation Institute of Chicago and the Ann & Robert H. Lurie Children’s Hospital of Chicago to deliver high quality multi-disciplinary patient care, while assessing QOL and functional outcomes.

Contact Dr. Kumthekar at 312.503-1818 or p-kumthekar@northwestern.edu

**Andrew Parsa, MD, PhD**, is Michael J. Marchese Professor and Chair in Neurological Surgery at Feinberg. His basic science interest is to understand the mechanism of GBM-mediated immunosuppression, identify effective means for reversing immunosuppression, and optimize anti-glioma vaccine therapies. Parsa is the Co-PI on a project in the UCSF brain SPORE focusing on implementation of a novel autologous vaccine strategy for patients with recurrent glioma. In addition, he has initiated a clinical trial evaluating the efficacy of this vaccine in primary glioma patients.

Contact Dr. Parsa at 312.695.1801 or andrew.parsa@northwestern.edu

**Meejeon Roh, PhD**, is Research Assistant Professor in Radiation Oncology at Feinberg. His primary interest is to identify novel molecular targets for prostate cancer (PCa) and is to test potential efficacy of such targets. Specifically, Roh’s lab has demonstrated that overexpression of Pim1 results in genomic instability, one of the hallmarks of human cancers. In an effort to identify molecular targets for PCa, he has identified the mitotic regulator polo-like kinase (PLK1) as a gene whose depletion is particularly detrimental to the viability of Pim1-expressing PCa cells *in vitro* and *in vivo*.

Contact Dr. Roh at 615.397.1965 or meejeon.roh@northwestern.edu

**Anjali Sharathkumar, MD**, is Assistant Professor in Pediatrics - Hematology / Oncology at Feinberg. Her clinical interest focuses on clinical translational research in hemostasis and thrombosis. Her research activities include: a risk prediction tool for thrombosis in children with critical illnesses such as cancer, long-term complications of thrombosis, and biomarkers of thrombosis. In addition, Sharathkumar is involved in Anticoagulation Quality improvement projects and the risk factors of thrombosis in children with brain tumor and ALL.

Contact Dr. Sharathkumar at 312.227.4836 or asharathkumar@luriechildrens.org
Lurie Cancer Center Social Media

Just a few short years ago, most of our interaction with colleagues and patients was done face to face, or over the phone. The brochures and pamphlets available to inform patients and families were often outdated by the time the ink dried.

Today, health-related information is available online 24/7. There are many great resources, but the magnitude can easily be overwhelming. By actively participating in social media, the Lurie Cancer Center is able to share accurate, timely information about patient care, research, patient and professional programs and more. Follow the Lurie Cancer Center on Facebook and Twitter to see what we’re up to, or better yet, join the conversation.

Best Doctors’ Physicians Guide to Getting Started on Twitter, describes it as a “Networking Reception that never ends. . .allowing for short updates on users’ interest or activities, opportunity to connect with those talking about your interests, ability to share content succinctly and with an engaged, far-reaching audience, and no reason to listen to those who have unrelated or irrelevant content.”

In the past few months we’ve helped a few Lurie Cancer Center physicians get started on Twitter. If you’re interested, or even just curious, please contact Jennifer Bowker at j-bowker@northwestern.edu or 312.695.0502.

» Read the Guide to Getting Started on Twitter

what’s new

News of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Office of Public Affairs and Communications - 676 N. St. Clair
Suite 1200
Chicago, IL 60611
312.695.1304

Director
Steven T. Rosen, MD, FACP

Director,
Public Affairs and Communications
Sharon Markman

Editorial Advisor
Tim Volpe

Managing Editor
Jennifer Bowker

Designer
Dana Cullum

Help Wanted: Reporters

PLEASE SEND SUGGESTIONS for this newsletter to Jennifer Bowker, j-bowker@northwestern.edu

Lurie Cancer Center Weekly Updates

INFORMATION TO BE CONSIDERED for inclusion in the Lurie Cancer Center’s weekly e-mail updates must be received at least one week in advance. Submit suggestions to Denise Marshall at d-marshall4@northwestern.edu.